ABSTRACT
Background: In 2013 the Chilean regulatory sanitary agency issued a warning concerning dose adjustment and use restriction to avoid severe adverse effects of metoclopramide such tardive dyskinesia. Aim: To study dyskinesia type adverse effects in a population using metoclopramide. Material and Methods: A cross sectional observational study was conducted among patients pertaining to palliative care and diabetes mellitus programs and consuming 10 mg/day or more of metoclopramide. Patients were interrogated looking for extrapiramidal signs and symptoms using a questionnaire validated by two neurologists. Results: In 40% of diabetic patients with gastroparesia and 35% of palliative care patients, extrapyramidal adverse reactions to metoclopramide were suspected. Palliative Care patients suffered the largest number of adverse events. The period of use and individual doses of the drug were largely above Chilean regulatory agency recommendations in all cases. Conclusions: A significant number of patients using metoclopramide could experience extrapyramidal adverse reactions.
Subject(s)
Humans , Male , Female , Pain/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Dopamine D2 Receptor Antagonists/adverse effects , Metoclopramide/adverse effects , Palliative Care , Chile , Cross-Sectional Studies , Surveys and Questionnaires , Pharmacovigilance , Dopamine D2 Receptor Antagonists/administration & dosage , Metoclopramide/administration & dosageABSTRACT
En los últimos años los estudios en pacientes con neuropatías han reveladocambios bioquímicos importantes que han explicado la pérdida de la visión por lesiones del nervio óptico con desmielización al nivel de la zona axial del nervio y en la cual los aminoácidos azufrados desempeñan un importante papel metabólico. Este estudio se encaminó a determinar la concentración plasmática de aminoácidos en pacientes con neuropatía epidémica diagnósticados en Cuba. Se encontró que la concentración plasmática de aminoácidos azufrados no cambió respecto al grupo control, por lo que creemos que el factor tóxico tenga un papel primordial. Sin embargo, se encontraron variaciones importantes en un grupo de aminoácidos que pensamos pueda deberse a cambios metabólicos de carácter nutricional que generalmente acpmpañan a esta enfermedad